Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback

SAN DIEGO, Nov. 18, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has received feedback in response to its previously...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news